This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Double-blind, Placebo-Controlled Trial

Peter J. Schmidt, MD; Gay N. Grover, RN, MSN; David R. Rubinow, MD

Arch Gen Psychiatry. 1993;50(6):467-473.

Abstract
Objective
To evaluate the efficacy of alprazolam in the treatment of premenstrual syndrome.

Design
A randomized, double-blind, placebo-controlled, crossover trial of alprazolam during eight menstrual cycles.

Setting
Outpatient clinic at the National Institute of Mental Health, Bethesda, Md.

Participants
Twenty-two women with prospectively confirmed premenstrual syndrome entered this study. All subjects were either self-referred or were referred by their physicians. All reported having regular menstrual cycle lengths, were taking no medication, and were free of current or recent medical or psychiatric illness. Two subjects did not complete the trial.

Intervention
Participants were assigned to receive alprazolam or placebo as follows: cycle 1, 0.25 mg of alprazolam or placebo three times daily beginning on menstrual cycle day 16; cycle 2, 0.50 mg of alprazolam or placebo three times daily according to the regimen during the first cycle; cycles 3 and 4, 0.75 mg of alprazolam or placebo three times daily from menstrual cycle day 16 and continued throughout the fourth menstrual cycle to evaluate the efficacy of relatively long-term (approximately 6 weeks) treatment with alprazolam.

Main Outcome Measures
Daily self-report symptoms ratings were completed during the entire study period.

Results
We observed no significant differences in the severity of premenstrual symptom ratings during alprazolam administration compared with placebo on any scale except the Beck Depression Inventory Scale. The Beck Depression Inventory ratings demonstrated a statistically (F_1,19=7.1, P<.05), but not clinically, significant improvement in depressive symptoms during alprazolam administration compared with placebo.

Conclusion
Our findings do not support alprazolam as a uniformly effective treatment for the symptoms of premenstrual syndrome.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Management Strategies for Premenstrual Syndrome/Premenstrual Dysphoric Disorder
Jarvis et al.
The Annals of Pharmacotherapy 2008;42:967-978.
ABSTRACT | FULL TEXT  

Premenstrual Dysphoric Disorder
Grady-Weliky
NEJM 2003;348:433-438.
FULL TEXT  

Luteal Phase Sertraline Treatment for Premenstrual Dysphoric Disorder: Results of a Double-blind, Placebo-Controlled, Crossover Study
Jermain et al.
Arch Fam Med 1999;8:328-332.
ABSTRACT | FULL TEXT  

Symptomatic Improvement of Premenstrual Dysphoric Disorder With Sertraline Treatment: A Randomized Controlled Trial
Yonkers et al.
JAMA 1997;278:983-988.
ABSTRACT  

A Double-blind Trial of Oral Progesterone, Alprazolam, and Placebo in Treatment of Severe Premenstrual Syndrome
Freeman et al.
JAMA 1995;274:51-57.
ABSTRACT  

Fluoxetine in the Treatment of Premenstrual Dysphoria
Steiner et al.
NEJM 1995;332:1529-1534.
ABSTRACT | FULL TEXT